Why local life sciences sector is keeping eye on Thar's IPO
Thar Pharmaceuticals Inc.'s pending $50 million initial public offering is catching the interest of other players in Pittsburgh's life sciences and biotech sector for two reasons.
First, it's been three years since the last local tech IPO, and the most recent life science offering looms more distantly. So the watch is on for how investors react to the deal and how Thar fares.
'People will watch to see what happens, and it may open the door for other companies to give it a shot,' said...